KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors (GPCRs), today announced that data highlighting its preclinical TRV250 program will be presented in an oral presentation at the International Headache Congress being held in Valencia, Spain, May 14-17, 2015.
Help employers find you! Check out all the jobs and post your resume.
